Specialty Pharmacy ContinuumCan ‘TrumpRx’ Move The Needle on Soaring Drug Prices?

The White House partnered with Pfizer to launch “TrumpRx”, a voluntary program offering discounted branded drugs through government website and MFN-style Medicaid pricing. According to experts, the plan lacks mandatory participation, pricing transparency, or enforcement mechanisms, and the limited reach won’t significantly reduce patient drug costs.

🏥 PROFESSIONAL IMPACT

• Pfizer’s “voluntary” MFN Medicaid pricing may not beat current statutory rebates on older products with large list-price increases—net savings uncertain without disclosed terms
• Direct-to-consumer TrumpRx website duplicates existing discount platforms (GoodRx, Cost Plus Drugs) and excludes insured patients—some competitors already offer lower prices
• Single-manufacturer agreement creates no precedent for industry-wide adoption—other drugmakers face no obligation to participate in voluntary discount program
• PBM bypass allows manufacturers to sidestep rebate negotiations but preserves manufacturer control over launch pricing and list-price inflation

🎯 ACTION ITEMS

• Compare TrumpRx cash prices against GoodRx and Cost Plus Drugs before directing uninsured patients to new platform
• Counsel patients that voluntary discounts may be temporary—no regulatory framework guarantees price stability or program continuation
• Educate patients that uninsured-only access excludes those with employer coverage, Medicare, Medicaid—benefits limited to narrow population segment
• Monitor whether additional manufacturers join program—single-company participation indicates limited industry commitment to price reduction

More in Healthcare Costs